Report: Bausch & Lomb nears deal to sell itself to Valeant for $9B

May 24, 2013 at 2:55 PM

ROCHESTER, N.Y., May 24 (UPI) -- Bausch & Lomb Inc. is nearing a deal to be sold to Valeant Pharmaceuticals International Inc. for about $9 billion, The Wall Street Journal reported Friday.

Citing people familiar with the situation, the newspaper said Bausch & Lomb -- based in Rochester, N.Y., and owned by private-equity firm Warburg Pincus LLC -- could reach a deal with generic drug maker Valeant by next week.

One source cautioned the deal hasn't been finalized and could still collapse.

If the sale falls through, Warburg and Bausch & Lomb could go ahead with a planned initial public offering of stock in the eye-care company, the Journal said.

Related UPI Stories
Latest Headlines
Trending Stories
Vatican: Bishops not required to report abuse
Former military doctors call for end to live tissue training
Nicola Griffin to appear in Sports Illustrated swimsuit issue at 56
Slovenian town plans public beer fountain
Congressional Black Caucus to endorse Clinton after N.H. primary loss to Sanders